Can GMRE sustain its EPS growth into 2025?

**Global Medical REIT (GMRE) is likely to face challenges in sustaining its EPS growth into 2025.** Here's why:

1. **Recent Organizational Changes and Tenant Bankruptcy Impact**: The company has recently undergone organizational changes and experienced a tenant bankruptcy, which has posed financial challenges. These factors could potentially affect GMRE's earnings per share (EPS) growth as they navigate through the aftermath of these events.
2. **Analyst Ratings and Price Targets**: The consensus rating for GMRE is "Neutral" with an average current price target that suggests the market is cautious about the stock's future performance. This could indicate that analysts are not yet convinced of GMRE's ability to sustain EPS growth.

3. **Interest Rate Impact on Debt Costs**: GMRE's floating rate debt costs are expected to marginally above 5% in 2025, which could impact the company's financials and potentially affect EPS growth. The company's weighted average interest cost is expected to increase due to the dominance of low-cost fixed-rate debt.
4. **Historical Performance and Forecasts**: There is no available data on GMRE's EPS growth rate, and the most recent EPS of $0.02 for Q4 2024 exceeded forecasts, but this does not necessarily indicate a trend that can be sustained.
5. **Market Conditions and Strategic Moves**: GMRE has been active in strategic acquisitions and joint ventures, which could positively influence its portfolio and potentially its EPS growth. However, the success of these moves in sustaining EPS growth will depend on market conditions and the company's execution.

In conclusion, while GMRE has shown stronger-than-expected earnings in Q4 2024, the challenges posed by organizational changes, tenant bankruptcy, and interest rate impacts on debt costs suggest that sustaining EPS growth into 2025 may be difficult. The company's ability to navigate these challenges and sustain EPS growth will depend on its strategic initiatives and market conditions.